Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2024

01-04-2024 | Lamotrigine | Case report

Lamotrigine/levetiracetam

Toxic optic neuropathy

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Chou M, et al. Toxic optic neuropathy associated with lamotrigine and levetiracetam dual therapy. BMJ Case Reports 17: No. 3, Jan 2024. Available from: URL: https://​dx.​doi.​org/​10.​1136/​bcr-2023-256961 [Summarised from an abstract]
Metadata
Title
Lamotrigine/levetiracetam
Toxic optic neuropathy
Publication date
01-04-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56892-9

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Antihypoglycaemics/hydrocortisone/octreotide

Case report

Bevacizumab/Temozolomide

Case report

Pioglitazone/Rosiglitazone

Case report

Octreotide/Pasireotide

News item

PRAC meeting highlights April 2024

Case report

Amikacin/carboplatin